Quick Answer
Atopic dermatitis affects ~16.5 million US adults (7.3%) and ~9.6 million US children (13%). Globally, ~223–230 million people have eczema. Approximately 33–40% have moderate-to-severe disease. Annual US direct costs reach ~$5.3 billion; biologic therapies have transformed treatment for severe cases but represent significant cost. Itch-driven sleep disruption affects ~60% of children with AD nightly.
Key Statistics at a Glance
Prevalence by Severity and Demographics
| Category | Statistic | Source |
|---|---|---|
| US adult prevalence | 7.3% (~16.5M) | Silverberg et al., JAMA Dermatol 2021 |
| US childhood prevalence | 13.0% (~9.6M) | CDC NHIS 2021 |
| Global prevalence | ~223–230 million | Deckers et al., JACI 2017 |
| Moderate-to-severe proportion (adults) | ~33–40% | IGA-based population surveys |
| Black children — US prevalence | ~18–19% (higher than general population) | Kaufman et al., J Invest Dermatol 2018 |
| Urban vs rural prevalence (children) | Urban ~40% higher risk | Multiple epidemiological studies |
| Prevalence in infants (under 2) | ~15–20% | Earliest-onset atopic condition |
| Adult-onset AD (first episode after age 18) | ~25–30% of adult cases | PEER consortium data |
Trend Analysis: Rising Prevalence
Atopic dermatitis prevalence has approximately doubled in high-income countries since the mid-20th century. The most reliable longitudinal data comes from repeated cross-sectional studies (ISAAC Phase I, II, and III) conducted across more than 100 countries. ISAAC data shows that the highest eczema prevalence rates are found in Anglophone countries (UK, Australia, New Zealand, US) and parts of Sub-Saharan Africa, while the lowest rates are in China, Central Asia, and parts of Eastern Europe.
The pattern of rising prevalence has not been linear everywhere — some high-income countries (UK, Australia) show plateau or even slight decreases in childhood eczema in the most recent surveys, while prevalence continues rising in newly industrializing and urbanizing regions. This pattern supports the hygiene hypothesis and its newer refinements (old friends hypothesis, biodiversity hypothesis). The data and hypotheses are detailed in our allergy research center.
Quality of Life and Burden of Disease
| QoL Domain | Finding | Source |
|---|---|---|
| Sleep disruption | ~60% of children; ~33% of adults report nightly itch disrupting sleep | Camfferman et al., Sleep Med Rev 2010 |
| School absences | Children with AD miss ~3–4 more school days/year than unaffected peers | [Source: US population-based school data — verify] |
| Mental health comorbidity | AD patients have 2–3× higher rates of anxiety and depression | Thyssen et al., BJD 2018; multiple studies |
| DLQI impairment (adults) | Moderate-severe AD: DLQI scores comparable to chronic pain, diabetes | Validated QoL instrument comparison studies |
| Caregiver burden | Parents of children with AD lose ~4–6 hours of sleep/night at peak flares | Lewis-Jones et al., CDLQI data |
| Work productivity loss | ~3–5 hours of productive work lost per week for moderate-severe adults | Severity-specific work productivity data |
What the Data Means
The eczema data makes a strong case for treating atopic dermatitis as a serious chronic disease rather than a cosmetic nuisance. The sleep, mental health, and productivity burden — particularly in moderate-to-severe disease — is comparable to conditions that receive far more systematic management and insurance coverage. The introduction of dupilumab in 2017 marked a turning point: the first biologic targeting the underlying Th2 pathway achieved clinical trial response rates (EASI-75) of 75–80% in pivotal studies, dramatically changing the treatment landscape for severe AD.
Access equity remains a challenge: dupilumab's pre-insurance cost exceeds $30,000 annually, and prior authorization requirements create significant barriers for patients in lower-income brackets. Research into accessible, low-cost skin barrier interventions (emollient therapy, soap avoidance) is ongoing, with prevention data showing that early and consistent emollient therapy in high-risk infants can delay or prevent AD development. See the full statistics hub and global allergy statistics for comparative international data.
Data Sources & Methodology Note
Primary sources: Silverberg JI et al., JAMA Dermatology 2021 (US adult prevalence); CDC NHIS 2021 (childhood AD); Deckers IAG et al., JACI 2017 (global burden); Eczema cost data from Drucker AM et al., JACI 2017; Simpson EL et al., NEJM 2016 (dupilumab Phase 3). Quality-of-life data from DLQI instrument publications. Racial/ethnic disparity data from Kaufman BP et al., Journal of Investigative Dermatology 2018. Biologic drug costs reflect US list prices; net prices after negotiation are typically lower.